GDUFA: Review Costs Continued To Climb Once Formal Review Goals Began
Executive Summary
Generic drug reviews during the first year of formal review goals cost 70% more than during GDUFA's inaugural year.
You may also be interested in...
ANDA Approvals, Submissions Decline With New Review Goal Coming
Is a rush of generic applications seeking the 10-month clock on the way?
Woodcock's Legacy: CDER Organizational Improvements
In interview with the Pink Sheet, Center for Drug Evaluation and Research director discusses her 30-year career, retirement speculation, and upcoming projects.
Generic User Fee Talks Reach 'Final Wording' But Still Not Done
FDA and industry say they have reached tentative agreement, but finance subgroup says more discussion needed.